Studies investigate the discriminatory capacity of existing prognostic scales and the factors associated with survival to help select patients who may benefit from participation in early phase trials
Addressing cost and affordability issues is now key to increasing the use of this approach in the clinical setting in Asia
Successful partnerships between industry and academia has had a positive impact on cancer drug discovery and development in prostate cancer
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Safety and efficacy data of some novel immunotherapy agents are encouraging, but more research is needed to identify biomarkers and the optimal treatment schedule
Scarcity of prospective data was reported as well as a limited use of real-world evidence as definitive evidence to regulatory approval decisions of targeted therapies in Europe
ESMO is at the forefront of digital oncology, with some initiatives that support oncologists navigating the emerging opportunities in the field of real-world data research
Liquid biopsies hold great promise in precision medicine in breast cancer, as shown by the pioneering work of Prof. Nicholas Turner, recipient of the ESMO Award for Translational Research 2023
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.